WST Net income
Net income at West Pharmaceutical Services rose to $494M in fiscal 2025, from $493M in 2024.
Net income attributable to the parent / common stockholders, as filed.
SOURCE: us-gaap:NetIncomeLoss · EDGAR CompanyFacts · CIK 105770 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
FY2025$494M
FY2024 $493M
HIGH$662M FY2021
LOW$493M FY2024
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Net income | Change |
|---|---|---|
| FY2025 | $494M | +$1M |
| FY2024 | $493M | $-101M |
| FY2023 | $593M | +$8M |
| FY2022 | $586M | $-76M |
| FY2021 | $662M | — |
More SAME DATA, OTHER VIEWS
Net income across coverage → · WST company view →
Revenue · Operating cash flow · Free cash flow · Capital expenditure · Cash & equivalents · Total assets · Shareholders' equity · Total debt · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.